Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

2,688 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Evolution of older patients diagnosed with early breast cancer in Spain between 1998 and 2001 included in El Alamo III project.
Torregrosa MD, Escudero MJ, Paredero I, Carrasco E, Bermejo B, Gavila J, García-Saenz J, Santaballa A, Martínez P, Llombart A, Andrés R, Batista N, Fernández A, Antón A, Seguí M, Gonzalez S, Ruiz A; GEICAM, the Spanish Breast Cancer Group. Torregrosa MD, et al. Among authors: ruiz a. Clin Transl Oncol. 2019 Dec;21(12):1746-1753. doi: 10.1007/s12094-019-02189-6. Epub 2019 Aug 5. Clin Transl Oncol. 2019. PMID: 31385227
Prognostic role for the derived neutrophil-to-lymphocyte ratio in early breast cancer: a GEICAM/9906 substudy.
Templeton AJ, Rodríguez-Lescure Á, Ruíz A, Alba E, Calvo L, Ruíz-Borrego M, Santaballa A, Rodríguez CA, Crespo C, Ramos M, Gracia-Marco JM, Lluch A, Álvarez I, Casas MI, Sánchez-Aragó M, Caballero R, Carrasco E, Amir E, Martin M, Ocaña A; GEICAM 9906 Study Investigators. Templeton AJ, et al. Among authors: ruiz borrego m, ruiz a. Clin Transl Oncol. 2018 Dec;20(12):1548-1556. doi: 10.1007/s12094-018-1885-5. Epub 2018 May 15. Clin Transl Oncol. 2018. PMID: 29766456
Phase II clinical trial of liposomal-encapsulated doxorubicin citrate and docetaxel, associated with trastuzumab, as neoadjuvant treatment in stages II and IIIA HER2-overexpressing breast cancer patients. GEICAM 2003-03 study.
Antón A, Ruiz A, Plazaola A, Calvo L, Seguí MA, Santaballa A, Muñoz M, Sánchez P, Miguel A, Carrasco E, Lao J, Camps J, Alfaro J, Antolín S, Cámara MC. Antón A, et al. Among authors: ruiz a. Ann Oncol. 2011 Jan;22(1):74-79. doi: 10.1093/annonc/mdq317. Epub 2010 Jul 5. Ann Oncol. 2011. PMID: 20603435 Free article. Clinical Trial.
Preventive treatments for breast cancer: recent developments.
Alés-Martínez JE, Ruiz A, Chacón JI, Lluch Hernández A, Ramos M, Córdoba O, Aguirre E, Barnadas A, Jara C, González S, Plazaola A, Florián J, Andrés R, Sánchez Rovira P, Frau A. Alés-Martínez JE, et al. Among authors: ruiz a. Clin Transl Oncol. 2015 Apr;17(4):257-63. doi: 10.1007/s12094-014-1250-2. Epub 2014 Dec 2. Clin Transl Oncol. 2015. PMID: 25445174 Free PMC article. Review.
A definition for aggressive disease in patients with HER-2 negative metastatic breast cancer: an expert consensus of the Spanish Society of Medical Oncology (SEOM).
González A, Lluch A, Aba E, Albanell J, Antón A, Álvarez I, Ayala F, Barnadas A, Calvo L, Ciruelos E, Cortés J, de la Haba J, López-Vega JM, Martínez E, Muñoz M, Peláez I, Redondo A, Rodríguez Á, Rodríguez CA, Ruíz A, Llombart A. González A, et al. Among authors: ruiz a. Clin Transl Oncol. 2017 May;19(5):616-624. doi: 10.1007/s12094-016-1571-4. Epub 2016 Nov 16. Clin Transl Oncol. 2017. PMID: 27853985 Review.
Outcomes of single versus double hormone receptor-positive breast cancer. A GEICAM/9906 sub-study.
Ethier JL, Ocaña A, Rodríguez Lescure A, Ruíz A, Alba E, Calvo L, Ruíz-Borrego M, Santaballa A, Rodríguez CA, Crespo C, Ramos M, Gracia Marco J, Lluch A, Álvarez I, Casas M, Sánchez-Aragó M, Carrasco E, Caballero R, Amir E, Martin M. Ethier JL, et al. Among authors: ruiz borrego m, ruiz a. Eur J Cancer. 2018 May;94:199-205. doi: 10.1016/j.ejca.2018.02.018. Epub 2018 Mar 21. Eur J Cancer. 2018. PMID: 29573665
Phase I clinical trial of liposomal-encapsulated doxorubicin citrate and docetaxel, associated with trastuzumab, as neo-adjuvant treatment in stages II and IIIA, HER2-overexpressing breast cancer patients. GEICAM 2003-03 study.
Antón A, Ruiz A, Seguí MA, Calvo L, Muñoz M, Lao J, Sancho F, Fernández L. Antón A, et al. Among authors: ruiz a. Ann Oncol. 2009 Mar;20(3):454-9. doi: 10.1093/annonc/mdn663. Epub 2008 Dec 11. Ann Oncol. 2009. PMID: 19074216 Free article. Clinical Trial.
Toxicity and health-related quality of life in breast cancer patients receiving adjuvant docetaxel, doxorubicin, cyclophosphamide (TAC) or 5-fluorouracil, doxorubicin and cyclophosphamide (FAC): impact of adding primary prophylactic granulocyte-colony stimulating factor to the TAC regimen.
Martín M, Lluch A, Seguí MA, Ruiz A, Ramos M, Adrover E, Rodríguez-Lescure A, Grosse R, Calvo L, Fernandez-Chacón C, Roset M, Antón A, Isla D, del Prado PM, Iglesias L, Zaluski J, Arcusa A, López-Vega JM, Muñoz M, Mel JR. Martín M, et al. Among authors: ruiz a. Ann Oncol. 2006 Aug;17(8):1205-12. doi: 10.1093/annonc/mdl135. Epub 2006 Jun 9. Ann Oncol. 2006. PMID: 16766587 Free article. Clinical Trial.
Phase II study of capecitabine in combination with paclitaxel in patients with anthracycline-pretreated advanced/metastatic breast cancer.
Batista N, Perez-Manga G, Constenla M, Ruiz A, Carabantes F, Castellanos J, Gonzalez Barón M, Villman K, Söderberg M, Ahlgren J, Casinello J, Regueiro P, Murias A. Batista N, et al. Among authors: ruiz a. Br J Cancer. 2004 May 4;90(9):1740-6. doi: 10.1038/sj.bjc.6601784. Br J Cancer. 2004. PMID: 15150624 Free PMC article. Clinical Trial.
2,688 results